Navigation Links
Transplanted human placenta-derived stem cells show therapeutic potential in stroke models
Date:2/1/2011

Human amniotic epithelial cells, stem cells derived from human placenta left over from live births and generally discarded, proliferated and differentiated when they interacted with one kind of melatonin receptor, MT1. This potentially therapeutic response occurred when the stem cells were transplanted into laboratory test tube and animal models of stroke. The same cells did not perform similarly when interacting with melatonin receptor MT2.

Researchers from the University of South Florida's Department of Neurosurgery and Brain Repair, and co-researchers in Brescia, Italy, concluded that the placenta-derived stem cells and their interaction with MT1 promoted functional recovery in the laboratory mice with modeled stroke.

Their study is published in the current issue of the Journal of Pineal Research.

"Along with increasing cell proliferation and survival rate, MT1 also enhanced the differentiation of placenta-derived stem cells into neuronal cells," said the study's lead author, Yuji Kaneko, PhD, a researcher with the USF Center of Excellence for Aging and Brain Repair. "Targeting the MT1 receptor could be beneficial as MT1 appears to enhance cell proliferation."

According to Dr. Kaneko, placenta-derived stem cells are pluripotent - able to differentiate into many types of cells - and current research is geared toward investigating their ability to differentiate into neuronal cells for the purpose of brain repair. Dr. Kaneko and colleagues examined how stem cells "express" specific melatonin receptors. MT1 is one of two kinds of melatonin found in humans, the primary hormone secreted by the pineal gland. The MT1 receptor is a membrane protein located in specific regions of the brain.

Although their research focused on models of stroke, the researchers concluded that human amniotic epithelial cell-melatonin treatment could also be useful in treating oxidative stress. Additionally, and consistent with past studies, they found high levels of vascular endothelial growth factor acting in concert with melatonin. They suggest that MT1's "solicitation' of this growth factor might have contributed to how amniotic epithelial cells and MT1 worked together to produce a neuroprotective effect while the placenta-derived stem cells and MT2 did not.

"This 'cross-talk' between melatonin and stem cells is an under explored research area," Dr. Kaneko said.

Their results, said Dr. Kaneko, advance the concept of melatonin receptor technology in stem cell therapy by which stem cells can be switched on with melatonin treatment, or switched off by withholding melatonin.

"This melatonin receptor technology can facilitate the regulation of stem cell growth and differentiation as well as the stimulation of the cell's growth factor secretory capacity," he concluded.


'/>"/>

Contact: Randolph Fillmore
rfillmor@health.usf.edu
813-974-0868
University of South Florida (USF Health)
Source:Eurekalert

Related medicine news :

1. Immune system helps transplanted stem cells navigate in central nervous system
2. Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue
3. New Period of Brain ‘Plasticity' Created with Transplanted Embryonic Cells
4. Cancer-targeting investigational nanoparticle receives FDA IND approval for first-in-human trial
5. Wild Hogs in Texas Pose Infection Risk to Humans
6. Researchers reveal function of novel molecule that underlies human deafness
7. Illegal use of human growth hormone common among young male weightlifters
8. Like humans, amoebae pack a lunch before they travel
9. Speaker series highlights the role of animals in human culture
10. Obesity in horses could be as high as in humans
11. Study details how protein made by HPV teams up on and thwarts protective human protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... ... County, as well as Palm Desert, is opening a new office in San ... deep transcranial magnetic stimulation (dTMS) in Southern California, successfully treating individuals struggling with ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from New York’s ... care practitioners on the latest breakthroughs in the prevention, diagnosis and treatment of ... according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of SightMD ...
(Date:1/17/2017)... ... 17, 2017 , ... Wettstein Agencies, a Denver area firm ... throughout central Colorado, is joining local nonprofit Aurora Warms The Night to provide ... organization is committed to breaking the cycle of homelessness and poverty affecting a ...
(Date:1/17/2017)... ... January 17, 2017 , ... Physicians Education Review®, LCC (PER®) ... speaker for the 34th Annual Miami Breast Cancer Conference®, on March 9-12, 2017 ... Phil Talamo, said, “We are delighted to have Sandra Lee join us as ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, FloSports , a global leader in ... agreement as part of a long-term extension of their media partnership. The partnership, which ... some of the sport’s premier events exclusively on FloWrestling.com as well as usage of ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Research and Markets has announced the addition of the "Active ... (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, Rx), Therapy (Diabetes, Oncology, ... offering. ... global active pharmaceutical ingredients market is expected to reach USD 213.97 ... a CAGR of 6.3% from 2016 to 2021. ...
(Date:1/17/2017)... 17, 2017 Immune Pharmaceuticals (NASDAQ: ... today that it will hold a Satellite Symposium on February ... (ISAL) XVI in Munich, Germany . ... Efficacy of Immunotherapy for the maintenance of remission in ... 20 th , 2017 from 12:45 – 13:45 CET ...
(Date:1/17/2017)... Interpace Diagnostics Group, Inc., (NASDAQ: IDXG ... tests and pathology services for evaluating risks of cancer, ... January 13, 2017 from the NASDAQ Listing Qualifications notifying ... requirement of the NASDAQ Stock Market to maintain a ... The letter noted that for the last 10 ...
Breaking Medicine Technology: